Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PALINASDAQ:PBLANASDAQ:QTNTNASDAQ:VIVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePALIPalisade Bio$0.62-3.6%$0.72$0.60▼$4.89$2.96M1.36547,719 shs75,148 shsPBLAPanbela Therapeutics$0.23+1.2%$0.27$0.20▼$0.47$1.14M1.3518,550 shs26,922 shsQTNTQuotient$0.44$0.18▼$105.20$980K2.32437,886 shs5.81 million shsVIVEViveve Medical$0.00+900.0%$0.00$0.00▼$0.02$11K0.112,956 shs1,569 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePALIPalisade Bio0.00%-3.56%-23.51%-11.94%-87.17%PBLAPanbela Therapeutics0.00%-21.77%-1.01%-27.34%-38.24%QTNTQuotient0.00%0.00%0.00%0.00%0.00%VIVEViveve Medical0.00%+900.00%+900.00%+400.00%+233.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPALIPalisade Bio1.9894 of 5 stars3.53.00.00.00.60.01.3PBLAPanbela Therapeutics0.0452 of 5 stars0.03.00.00.00.00.00.0QTNTQuotientN/AN/AN/AN/AN/AN/AN/AN/AVIVEViveve MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePALIPalisade Bio 3.00Buy$12.001,843.95% UpsidePBLAPanbela Therapeutics 2.00HoldN/AN/AQTNTQuotient 0.00N/AN/AN/AVIVEViveve Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QTNT, PALI, VIVE, and PBLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025PALIPalisade BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPALIPalisade Bio$250K11.85N/AN/A$2.71 per share0.23PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/AQTNTQuotient$38.51M0.00N/AN/A($56.17) per share0.00VIVEViveve Medical$6.83M0.00N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePALIPalisade Bio-$14.44M-$6.80N/AN/AN/AN/A-178.96%-127.35%8/11/2025 (Estimated)PBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%8/11/2025 (Estimated)QTNTQuotient-$125.13M-$53.21N/AN/AN/A-413.55%N/A-88.21%N/AVIVEViveve MedicalN/AN/A0.00∞N/AN/AN/AN/AN/ALatest QTNT, PALI, VIVE, and PBLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PALIPalisade Bio-$0.84-$0.47+$0.37-$0.47N/AN/A3/24/2025Q4 2024PALIPalisade Bio-$2.39-$0.69+$1.70-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPALIPalisade BioN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/AQTNTQuotientN/AN/AN/AN/AN/AVIVEViveve MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPALIPalisade BioN/A2.842.84PBLAPanbela TherapeuticsN/A0.260.26QTNTQuotientN/A1.791.36VIVEViveve MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPALIPalisade Bio11.79%PBLAPanbela Therapeutics4.37%QTNTQuotientN/AVIVEViveve MedicalN/AInsider OwnershipCompanyInsider OwnershipPALIPalisade Bio3.28%PBLAPanbela Therapeutics0.01%QTNTQuotient10.50%VIVEViveve Medical5.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePALIPalisade Bio104.80 million4.64 millionNot OptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableQTNTQuotient4262.58 million2.31 millionOptionableVIVEViveve Medical7010.67 millionN/ANot OptionableQTNT, PALI, VIVE, and PBLA HeadlinesRecent News About These CompaniesSharing medical andOctober 25, 2024 | news-medical.netViveve Medical Inc (VIVE)July 24, 2024 | investing.comIncontinence Devices Pipeline Research Report 2024: Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesJuly 19, 2024 | finance.yahoo.comVaginal Rejuvenation Is Big BusinessJuly 19, 2024 | ca.style.yahoo.com5-Alpha Reductase Deficiency Global Market Report 2024: A $1.94 Billion Projected Market in 2028April 17, 2024 | finance.yahoo.comInMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTLApril 15, 2024 | finance.yahoo.comViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsFebruary 23, 2024 | benzinga.comThe Best Medical Billing Services of 2024January 19, 2024 | business.comVIVE Viveve Medical, Inc.July 29, 2023 | seekingalpha.comInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve PatentsJuly 25, 2023 | finance.yahoo.comVIVE - Viveve Medical, Inc.June 14, 2023 | uk.finance.yahoo.comViveve Medical, Inc. (VIVE)February 24, 2023 | finance.yahoo.comViveve Medical announces study result from PURSUIT clinical trial to treat female stress urinary incontinenceJanuary 20, 2023 | pharmabiz.comWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJanuary 17, 2023 | msn.comViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | finanznachrichten.deViveve crashes ~60% as company decides to delist, explore sale after trial failsJanuary 17, 2023 | seekingalpha.comViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | finance.yahoo.comViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialJanuary 17, 2023 | finance.yahoo.comWhy Is Viveve Medical (VIVE) Stock Down 69% Today?January 17, 2023 | investorplace.comViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptDecember 29, 2022 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingX: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold BackBy Sam Quirke | June 7, 2025View X: 1 Reason to Bet on U.S. Steel, and 1 Reason to Hold BackQTNT, PALI, VIVE, and PBLA Company DescriptionsPalisade Bio NASDAQ:PALI$0.62 -0.02 (-3.62%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.63 +0.01 (+2.06%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Panbela Therapeutics NASDAQ:PBLA$0.23 +0.00 (+1.16%) As of 06/20/2025 03:37 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Quotient NASDAQ:QTNTQuotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.Viveve Medical NASDAQ:VIVE$0.0010 +0.00 (+900.00%) As of 06/20/2025 02:45 PM EasternViveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
